Siemens Healthineers: boosted by antigen tests
(CercleFinance.com) - On Wednesday Siemens Healthineers raised its FY earnings and sales forecasts, as it reported better-than-expected Q1 results.
The medical imaging specialist, which was floated by parent company Siemens in 2018, posted a 47% jump in its operating profit to 980 million euros in Q2, to end-March.
The consensus was looking for average earnings of 919 million euros.
The German group's comparable sales rose 15.8% to nearly 5.5 billion euros, again driven by its rapid antigen testing business.
Excluding the Covid tests, LFL sales were up 4.4%.
For FY 2021-2022, the group says that it now expects adjusted EPS of 2.25 to 2.35 dollars, up from 2.18-2.30 dollars previously, on organic sales growth of 5.5% to 7.5%, up from 3% to 5% previously.
At lunchtime today Siemens Healthineers shares were up about 0.8%, outperforming a slightly negative German market by around 1%.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The medical imaging specialist, which was floated by parent company Siemens in 2018, posted a 47% jump in its operating profit to 980 million euros in Q2, to end-March.
The consensus was looking for average earnings of 919 million euros.
The German group's comparable sales rose 15.8% to nearly 5.5 billion euros, again driven by its rapid antigen testing business.
Excluding the Covid tests, LFL sales were up 4.4%.
For FY 2021-2022, the group says that it now expects adjusted EPS of 2.25 to 2.35 dollars, up from 2.18-2.30 dollars previously, on organic sales growth of 5.5% to 7.5%, up from 3% to 5% previously.
At lunchtime today Siemens Healthineers shares were up about 0.8%, outperforming a slightly negative German market by around 1%.
Copyright (c) 2022 CercleFinance.com. All rights reserved.